Author(s):
Urfianty, Aidah Juliaty, Idham Jaya Ganda, Jumraini Tammase, Irfan Idris, Irawan Mangunatmadja, Muhammad Yunus Amran, Yanti Leman
Email(s):
urfiantysaid@yahoo.com
DOI:
10.52711/0974-360X.2025.00156 
Address:
Urfianty1,2*, Aidah Juliaty1, Idham Jaya Ganda1, Jumraini Tammase3, Irfan Idris2, Irawan Mangunatmadja4, Muhammad Yunus Amran3, Yanti Leman5
1Department of Pediatrics, Faculty of Medicine, Hasanuddin University, Makassar, 90245, South Sulawesi, Indonesia.
2Doctoral Program, Graduate School of Medicine, Hasanuddin University, Makassar, 90245, South Sulawesi, Indonesia.
3Department of Neurology, Faculty of Medicine, Hasanuddin University, Makassar, 90245, South Sulawesi, Indonesia.
4Departement of Pediatrics, Faculty of Medicine, University of Indonesia, Jakarta Pusat, 10430, Jakarta, Indonesia.
5Department of Pharmacology, Faculty of Medicine, Hasanuddin University, Makassar, 90245, South Sulawesi, Indonesia.
*Corresponding Author
Published In:
Volume - 18,
Issue - 3,
Year - 2025
ABSTRACT:
Antiseizure medications (ASMs) are frequently utilized either as ongoing supplementary treatment or as the primary therapy for epilepsy. Different ASMs either inhibit of induce isoenzymes of CYP450 system, potentially altering the pharmacokinetic characteristics of various medications, including in polytherapy of ASMs. This study investigate the interaction between CYP450 and ASMs, with emphasis on pharmacokinetic interactions. This literature study included publications from the last 5 years (2018-2023) that are relevant to the topic and important publications retrieved and reviewed from the PubMed, ResearchGate, and Google Scholar databases by using a combination of main keywords "antiseizure medications", "cytochrome P450", "pharmacokinetics", "metabolism" and other relevant keywords. It was found that due to the role of CYP450 enzymes in metabolizing most therapeutic drugs, individuals using ASMs that induce these enzymes may metabolize a diverse array of concurrently administered medications more rapidly, potentially leading to an increase in dosage requirements. Phenytoin, primidone, phenobarbital and carbamazepine enhance the function of various cytochrome P450 (CYP) enzymes, such as CYP2C9, CYP1A2, CYP3A4 and CYP2C19. On the other hand, inhibition of these enzymes could elevate the plasma level of drugs that are metabolized via those enzymes. Valproic acid and oxcarbazepine are the examples of CYP450 inhibitors. The majority of significant interactions involving ASMs in clinical contexts arise from either the stimulation or suppression of CYP450 drug-metabolizing enzymes. These interactions can lead to alterations in the pharmacokinetic characteristics of various medications. Typically, adjustments to the dosage of the affected AED are necessary. Additional research and investigations are necessary regarding possible interaction between CYP450 and newer ASMs to determine the possible outcome due to these interactions.
Cite this article:
Urfianty, Aidah Juliaty, Idham Jaya Ganda, Jumraini Tammase, Irfan Idris, Irawan Mangunatmadja, Muhammad Yunus Amran, Yanti Leman. Interaction between Cytochrome P450 Isozymes and Antiseizure Medications: A Literature Review. Research Journal Pharmacy and Technology. 2025;18(3):1089-5. doi: 10.52711/0974-360X.2025.00156
Cite(Electronic):
Urfianty, Aidah Juliaty, Idham Jaya Ganda, Jumraini Tammase, Irfan Idris, Irawan Mangunatmadja, Muhammad Yunus Amran, Yanti Leman. Interaction between Cytochrome P450 Isozymes and Antiseizure Medications: A Literature Review. Research Journal Pharmacy and Technology. 2025;18(3):1089-5. doi: 10.52711/0974-360X.2025.00156 Available on: https://rjptonline.org/AbstractView.aspx?PID=2025-18-3-17
REFERENCES:
1. World Health Organisation (WHO). Epilepsy. n.d. Available from: https://www.who.int/news-room/fact-sheets/detail/epilepsy [Last accessed: 12/28/2023].
2. NICE. Epilepsies in Children, Young People and Adults: Diagnosis and Management. National Institute for Health and Care Excellence: London; 2022.
3. Beghi E. The Epidemiology of Epilepsy. Neuroepidemiology. 2020; 54(2): 185–191. doi.org/ 10.1159/000503831.
4. Ranjan B. Suddhendu C. Debasish S. Sumita B. Madhab M. Jayita M et al. An Unique Case of Ito Syndrome Presenting with Juvenile Myoclonic Epilepsy and Normal Intelligence. International Journal of Psychology and Psychiatry. 2014; 2(2): 238. doi.org/ 10.5958/2320-6233.2014.00011.x.
5. Swedish Agency for Health Technology Assessment and Assessment of Social Services. Diagnosis and Treatments for Epilepsy: A Systematic Review and Assessment of the Medical, Health Economic, Social and Ethical Aspects [Internet]. 2018. Available from: https://www.ncbi.nlm.nih.gov/books/NBK570474/ [Last accessed: 12/28/2023].
6. Fisher RS. Cross JH. D’Souza C. French J. haut S. Higurashi N et al. Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia. 2017; 58(4): 531–542. doi.org/10.1111/epi.13671.
7. Jain P. Surana A. Pandey R. Shukla SS. Epilepsy: A Neurological Cramp. Research Journal of Pharmacology and Pharmacodynamics. 2013;5(1):1–5.
8. Riva A. Golda A. Balagura G. Amadori E. Vari MS. Piccolo G et al. New Trends and Most Promising Therapeutic Strategies for Epilepsy Treatment. Frontiers in Neurology. 2021; 12(December):1–14. doi.org/10.3389/fneur.2021.753753.
9. Mohan A. Ghosh S. New Method for Spectrophotometric Estimation of New Anti-Epileptic Drugs in Solid Dosage Form. Asian Journal of Research in Chemistry. 2009; 2(3): 322–324.
10. Subbarao BS. Eapen BC. Seizure Medications. StatPearls 2019; 1–8.
11. Johannessen SI. Landmark CJ. Antiepileptic Drug Interactions - Principles and Clinical Implications. Current Neuropharmacology. 2010; 8(3): 254–267. doi.org/10.2174/157015910792246254.
12. Khan PM. Jha A. Pathak S. Jha R. Khond S. Mujawar J. Antiepileptic Drug Utilization in Pediatric Patients at a Tertiary Care Rural Teaching Hospital of Central India. Research Journal of Pharmacology and Pharmacodynamics. 2015;7(1):5. doi.org/10.5958/2321-5836.2015.00002.6.
13. Verrotti A. Tambucci R. Di Francesco L. Pavone P. Iapadre G. Altobelli E et al. The role of polytherapy in the management of epilepsy: suggestions for rational antiepileptic drug selection. Expert Review of Neurotherapeutics. 2020; 20(2): 167–173. doi.org/10.1080/14737175.2020.1707668.
14. Vanitha K. Desu PK. Formulation Development and Evaluation of Sodium Valproate and Valproic acid Extended Release Tablets. Research Journal of Pharmaceutical Dosage Forms and Technology. 2019; 11(2): 74. doi.org/10.5958/0975-4377.2019.00012.0.
15. Verrotti A. Lattanzi S. Brigo F. Zaccara G. Pharmacodynamic interactions of antiepileptic drugs: From bench to clinical practice. Epilepsy and Behavior. 2020; 104: 106939. doi.org/10.1016/j.yebeh.2020.106939.
16. Shah YR. Sen DJ. Patel CN. Biochemical Role of Cytochrome P450 Enzymes In-Vivo. Asian Journal of Research in Chemistry. 2010; 3(2): 243–248.
17. Gilani B. Cassagno M. Biochemistry, Cytochrome P450. 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557698/ [Last accessed: 12/23/2023].
18. Lynch T. Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. American Family Physician. 2007; 76(3): 391–396.
19. Karaźniewicz-łada M. Główka AK. Mikulska AA. Główka F. Pharmacokinetic drug–drug interactions among antiepileptic drugs, including cbd, drugs used to treat covid-19 and nutrients. International Journal of Molecular Sciences. 2021; 22(17). doi.org/10.3390/ijms22179582.
20. Manikandan P. Nagini S. Cytochrome P450 Structure, Function and Clinical Significance: A Review. Current Drug Targets. 2017; 19(1): 38–54. doi.org/10.2174/1389450118666170125144557.
21. Vera-González A. Pathophysiological Mechanisms Underlying the Etiologies of Seizures and Epilepsy. Epilepsy. 2022;(Figure 1). doi.org/10.36255/exon-publications-epilepsy-pathopysiology.
22. Huff JS. Murr N. Seizure. 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430765/ [Last accessed: 12/23/2023].
23. Suresh D. Aggarwal M. Srivastava A. Singh M. A Comparative Study to Assess the Knowledge of Caregivers of People with Epilepsy and General Public Regarding Epilepsy and its First-Aid Management. Asian Journal of Nursing Education and Research. 2017; 7(2): 147. doi.org/10.5958/2349-2996.2017.00029.5.
24. Mammenand KA. Sathesh Kumar S. A prospective observational study on depression in epileptic patients. Research Journal of Pharmacy and Technology. 2017; 10(8): 2587–2590. doi.org/10.5958/0974-360X.2017.00459.0.
25. Shih JJ. Tatum WO. Rudzinski LA. New drug classes for the treatment of partial onset epilepsy: Focus on perampanel. Therapeutics and Clinical Risk Management. 2013; 9(1): 285–293. doi.org/10.2147/TCRM.S37317.
26. Hakami T. Neuropharmacology of Antiseizure Drugs. Neuropsychopharmacology Reports. 2021; 41(3): 336–351. doi.org/ 10.1002/npr2.12196.
27. Kim H. Kim DW. Lee ST. Byeon J. Seo J. No Y et al. Antiepileptic drug selection according to seizure type in adult patients with epilepsy. Journal of Clinical Neurology (Korea). 2020; 16(4): 547–555. doi.org/ 10.3988/jcn.2020.16.4.547.
28. Ratna B. Krishna B. Bhavani K. Investigation on the effect of the drug levetiracetam combined with clobazam on MES model of epilepsy. Research Journal of Pharmacy and Technology. 2020; 13(6): 2792–2796. doi.org/10.5958/0974-360X.2020.00496.5.
29. Sangeetha N. Rao USM. Hepatotoxic Effect of Sodium Valproate Therapy in Epileptic Children. 2011; 3(4): 135–138.
30. Peng Y. Cheng Z. Xie F. Evaluation of pharmacokinetic drug-drug interactions: A review of the mechanisms, in vitro and in silico approaches. Metabolites. 2021; 11(2): 1–16. doi.org/10.3390/metabo11020075.